AU2020346455B2 - Drug delivery formulations - Google Patents

Drug delivery formulations Download PDF

Info

Publication number
AU2020346455B2
AU2020346455B2 AU2020346455A AU2020346455A AU2020346455B2 AU 2020346455 B2 AU2020346455 B2 AU 2020346455B2 AU 2020346455 A AU2020346455 A AU 2020346455A AU 2020346455 A AU2020346455 A AU 2020346455A AU 2020346455 B2 AU2020346455 B2 AU 2020346455B2
Authority
AU
Australia
Prior art keywords
formulation
risperidone
poly
copolymer
biodegradable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020346455A
Other languages
English (en)
Other versions
AU2020346455A1 (en
Inventor
Eran HARARY
Anthony RECH
Christophe ROBERGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedinCell SA
Original Assignee
MedinCell SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedinCell SA filed Critical MedinCell SA
Publication of AU2020346455A1 publication Critical patent/AU2020346455A1/en
Application granted granted Critical
Publication of AU2020346455B2 publication Critical patent/AU2020346455B2/en
Priority to AU2025242078A priority Critical patent/AU2025242078A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2020346455A 2019-09-13 2020-09-11 Drug delivery formulations Active AU2020346455B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025242078A AU2025242078A1 (en) 2019-09-13 2025-09-30 Drug delivery formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900061P 2019-09-13 2019-09-13
US62/900,061 2019-09-13
PCT/IB2020/058474 WO2021048817A1 (en) 2019-09-13 2020-09-11 Drug delivery formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025242078A Division AU2025242078A1 (en) 2019-09-13 2025-09-30 Drug delivery formulations

Publications (2)

Publication Number Publication Date
AU2020346455A1 AU2020346455A1 (en) 2022-03-31
AU2020346455B2 true AU2020346455B2 (en) 2025-07-03

Family

ID=72521677

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020346455A Active AU2020346455B2 (en) 2019-09-13 2020-09-11 Drug delivery formulations
AU2025242078A Pending AU2025242078A1 (en) 2019-09-13 2025-09-30 Drug delivery formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025242078A Pending AU2025242078A1 (en) 2019-09-13 2025-09-30 Drug delivery formulations

Country Status (19)

Country Link
US (3) US12383493B2 (enExample)
EP (2) EP4027973B8 (enExample)
JP (2) JP7661312B2 (enExample)
KR (1) KR20220062372A (enExample)
CN (1) CN114727946A (enExample)
AU (2) AU2020346455B2 (enExample)
BR (1) BR112022004535A2 (enExample)
CA (1) CA3153793A1 (enExample)
DK (1) DK4027973T3 (enExample)
ES (1) ES3058225T3 (enExample)
FI (1) FI4027973T3 (enExample)
HR (1) HRP20251690T1 (enExample)
IL (1) IL291283A (enExample)
LT (1) LT4027973T (enExample)
MX (1) MX2022003051A (enExample)
PL (1) PL4027973T3 (enExample)
PT (1) PT4027973T (enExample)
SI (1) SI4027973T1 (enExample)
WO (1) WO2021048817A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511353A (ja) * 2021-03-17 2024-03-13 メドインセルル エス．エー． リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤
JP2026501805A (ja) * 2023-01-10 2026-01-16 メドインセルル エス．エー． オランザピン組成物及び使用の方法
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120172454A1 (en) * 2010-12-29 2012-07-05 Medincell Biodegradable drug delivery compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2299393A1 (en) 1997-08-08 1999-02-18 Sung Wan Kim Injectable biodegradable block copolymer gels for use in drug delivery
CA2474968A1 (en) 2002-01-31 2003-08-07 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
BRPI0919465A2 (pt) 2008-09-30 2015-12-01 Endo Pharmaceuticals Solutions dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo
CN101584652B (zh) 2009-06-19 2012-06-20 上海医药集团股份有限公司 利培酮缓释凝胶注射剂及其制备方法
US20130144250A1 (en) * 2011-10-24 2013-06-06 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
EP2866837B1 (en) 2012-06-27 2022-12-14 Medincell S.A. Biodegradable drug delivery for hydrophobic compositions
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
EP3655017B1 (en) 2017-07-17 2025-01-22 Medincell S.A. Pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120172454A1 (en) * 2010-12-29 2012-07-05 Medincell Biodegradable drug delivery compositions

Also Published As

Publication number Publication date
FI4027973T3 (fi) 2026-01-14
ES3058225T3 (en) 2026-03-09
JP2025106353A (ja) 2025-07-15
US20250268817A1 (en) 2025-08-28
EP4706658A2 (en) 2026-03-11
PL4027973T3 (pl) 2026-03-09
EP4027973B8 (en) 2025-12-17
CN114727946A (zh) 2022-07-08
LT4027973T (lt) 2026-01-26
IL291283A (en) 2022-05-01
WO2021048817A1 (en) 2021-03-18
CA3153793A1 (en) 2021-03-18
US12383493B2 (en) 2025-08-12
US12128132B2 (en) 2024-10-29
EP4027973B1 (en) 2025-11-05
PT4027973T (pt) 2026-01-05
AU2025242078A1 (en) 2025-10-23
BR112022004535A2 (pt) 2022-06-07
SI4027973T1 (sl) 2026-02-27
HRP20251690T1 (hr) 2026-02-13
AU2020346455A1 (en) 2022-03-31
JP2022548616A (ja) 2022-11-21
DK4027973T3 (da) 2026-01-12
EP4027973A1 (en) 2022-07-20
JP7661312B2 (ja) 2025-04-14
US20240156722A1 (en) 2024-05-16
MX2022003051A (es) 2022-06-14
US20220331240A1 (en) 2022-10-20
KR20220062372A (ko) 2022-05-16

Similar Documents

Publication Publication Date Title
US20250268817A1 (en) Drug delivery formulations
JP2017141307A (ja) タキサン系活性成分含有液体組成物及び液体製剤
JP2007515425A (ja) 医薬組成物
JP5872551B2 (ja) パラセタモールを含む医薬組成物およびその製造法
US12329851B2 (en) Long acting injectable formulation comprising risperidone and biodegradable polymers
AU2011273064A1 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
EP2709600A1 (en) Pharmaceutical composition comprising fexofenadine
BR122025009310A2 (pt) Formulações de entrega de fármaco
JP2007137869A (ja) 直腸、尿道および膣適用用半固形状製剤。
WO2021033145A1 (en) Novel injectable formulations of artesunate
CN116997323A (zh) 包含利培酮和可生物降解的聚合物的长效可注射制剂
ITMI20121154A1 (it) Soluzione iniettabile di acetaminofene per la somministrazione spinale
OA19944A (en) Pharmaceutical composition comprising fexofenadine.
AU2012260992A1 (en) Pharmaceutical composition comprising fexofenadine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)